Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology

SAN JOSE, Calif., Nov. 27, 2023 /PRNewswire/ — Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its partner, Cleveland Clinic, has received an “Intention to Grant” notice…

Click here to view original post